DMP — Dermapharm Holding SE Cashflow Statement
0.000.00%
Last trade - 00:00- €2.06bn
- €3.01bn
- €1.18bn
- 98
- 37
- 84
- 89
Annual cashflow statement for Dermapharm Holding SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 125 | 293 | 216 | 106 | 172 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 14 | 3.26 | 22.1 | 68 | 44.5 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -51.2 | -91.1 | -44.7 | -57.2 | -102 |
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 132 | 250 | 289 | 219 | 201 |
| Capital Expenditures | -40.8 | -61.2 | -39 | -41.5 | -38.2 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -65.1 | -68.1 | -60 | -374 | 8.62 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -106 | -129 | -99 | -415 | -29.6 |
| Financing Cash Flow Items | -22.7 | -7.69 | -11.7 | -33.1 | -53.7 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -14.1 | -81 | -200 | 205 | -209 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.3 | 41.1 | -10.4 | 7.71 | -37.4 |